Cargando…
PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428917/ http://dx.doi.org/10.1097/01.HS9.0000975284.03927.4c |
| _version_ | 1785090585499009024 |
|---|---|
| author | Grosicki, Sebastian Yeh, Su-Peng Huang, Shang-Yi Byun, Ja Min Dirienzo, Christine Viqueira, Andrea |
| author_facet | Grosicki, Sebastian Yeh, Su-Peng Huang, Shang-Yi Byun, Ja Min Dirienzo, Christine Viqueira, Andrea |
| author_sort | Grosicki, Sebastian |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428917 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104289172023-08-17 PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Grosicki, Sebastian Yeh, Su-Peng Huang, Shang-Yi Byun, Ja Min Dirienzo, Christine Viqueira, Andrea Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428917/ http://dx.doi.org/10.1097/01.HS9.0000975284.03927.4c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Grosicki, Sebastian Yeh, Su-Peng Huang, Shang-Yi Byun, Ja Min Dirienzo, Christine Viqueira, Andrea PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| title | PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| title_full | PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| title_fullStr | PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| title_full_unstemmed | PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| title_short | PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| title_sort | pb2130: magnetismm-6: a phase 3 study of elranatamab + daratumumab + lenalidomide vs daratumumab + lenalidomide + dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428917/ http://dx.doi.org/10.1097/01.HS9.0000975284.03927.4c |
| work_keys_str_mv | AT grosickisebastian pb2130magnetismm6aphase3studyofelranatamabdaratumumablenalidomidevsdaratumumablenalidomidedexamethasoneintransplantineligiblepatientswithnewlydiagnosedmultiplemyeloma AT yehsupeng pb2130magnetismm6aphase3studyofelranatamabdaratumumablenalidomidevsdaratumumablenalidomidedexamethasoneintransplantineligiblepatientswithnewlydiagnosedmultiplemyeloma AT huangshangyi pb2130magnetismm6aphase3studyofelranatamabdaratumumablenalidomidevsdaratumumablenalidomidedexamethasoneintransplantineligiblepatientswithnewlydiagnosedmultiplemyeloma AT byunjamin pb2130magnetismm6aphase3studyofelranatamabdaratumumablenalidomidevsdaratumumablenalidomidedexamethasoneintransplantineligiblepatientswithnewlydiagnosedmultiplemyeloma AT dirienzochristine pb2130magnetismm6aphase3studyofelranatamabdaratumumablenalidomidevsdaratumumablenalidomidedexamethasoneintransplantineligiblepatientswithnewlydiagnosedmultiplemyeloma AT viqueiraandrea pb2130magnetismm6aphase3studyofelranatamabdaratumumablenalidomidevsdaratumumablenalidomidedexamethasoneintransplantineligiblepatientswithnewlydiagnosedmultiplemyeloma |